Amgen to pay $200 million
From Times Wire Services
Amgen Inc. will pay Johnson & Johnson $200 million to settle an antitrust claim over discounts on Amgen’s drugs for cancer patients, the companies said.
Amgen, based in Thousand Oaks, admitted no liability in agreeing to pay the money to Ortho Biotech Products, a unit of Johnson & Johnson that accused Amgen of offering oncology clinics package discounts on their purchases of Aranesp, Neupogen and Neulasta.
